The company reported a net loss of $42,787,043 for the fiscal year ended December 31, 2025, an increase from $35,020,058 in 2024. Revenue decreased dramatically to $3,195 in 2025 from $133,985 in 2024, primarily due to decreased COVID testing. As of December 31, 2025, the cash balance was $3,198,599, and the accumulated deficit reached $209,808,770. Management explicitly stated that remaining funds are not sufficient to fund operations for the next 12 months, creating substantial doubt about the company's ability to continue as a going concern. The company is non-compliant with Nasdaq Listing Rule 5550(b)(1) requiring a minimum of $2,500,000 in stockholders' equity and received a delisting notice, though an extension was granted until May 15, 2026. The common stock traded below $1.00 for 6 consecutive trading days as of March 30, 2026, risking a minimum bid price deficiency, and its market capitalization was approximately $713,000, well below a proposed Nasdaq delisting threshold of $5.0 million. The merger agreement with Evofem Biosciences, Inc. was terminated on October 20, 2025, due to the end date passing and failure to obtain shareholder approval, though Aditxt retains its holdings of Evofem F-1 Preferred Stock, convertible notes, and warrants. The Appili Arrangement Agreement was terminated effective May 31, 2025, resulting in a $1,250,000 termination fee, with $750,000 remaining unpaid as of December 31, 2025. The company is developing ADI-100, an immune modulation therapeutic, with preclinical studies completed and human trials for Stiff Person Syndrome expected to begin in 2026. Pearsanta, a subsidiary, is developing molecular tests based on mitochondrial DNA for early detection of various cancers (prostate, endometriosis, ovarian, lung, pancreatic, liver, breast, stomach, esophageal, and colorectal). Pearsanta acquired patents related to Adductomics Technology on March 21, 2025, for comprehensive assessment of DNA adducts. On March 11, 2026, the company acquired Ignite Proteomics, LLC for 36,000 shares of newly created Series A-2 Convertible Preferred Stock, valued at $36,000,000. Multiple reverse stock splits were effectuated: 1-for-40 (Oct 2024), 1-for-250 (Mar 2025), 1-for-113 (Nov 2025), and 1-for-8 (Mar 2026). Material weaknesses in internal control over financial reporting were identified, including inadequate documentation of accounting policies and insufficient procedures for accounts payable and debt/equity transactions.